CAJ | 학술논문

目的：探讨放疗近期疗效与血清肿瘤标志物含量的关系。方法回顾性分析196例晚期非小细胞肺癌（ non-small-cell carcinoma ，NSCLC）患者放疗前后血清中CEA、CYFAR21-1、SCC、CA125的水平变化，同时通过临床症状等资料评价放疗的近期效果，以此探讨放疗的近期疗效与肿瘤标志物变化的关系。结果196例患者中有109例在接受放疗后有效，总有效率为55．61％。放疗有效的患者在放疗后常规检查血清中CEA、CYFAR21-1、SCC、CA125含量与放疗前比较，明显减少，且差异具有统计学意义（P＜0．05）；接受放疗后肿瘤标志物降低组的110例患者近期疗效显著好于升高组，差异具有统计学意义（P＜0．05）。结论血清肿瘤标志物CEA、CYFAR21-1、SCC、CA125的含量或可以用来评价放疗对晚期NSCLC的近期效果。
목적：탐토방료근기료효여혈청종류표지물함량적관계。방법회고성분석196례만기비소세포폐암（ non-small-cell carcinoma ，NSCLC）환자방료전후혈청중CEA、CYFAR21-1、SCC、CA125적수평변화，동시통과림상증상등자료평개방료적근기효과，이차탐토방료적근기료효여종류표지물변화적관계。결과196례환자중유109례재접수방료후유효，총유효솔위55．61％。방료유효적환자재방료후상규검사혈청중CEA、CYFAR21-1、SCC、CA125함량여방료전비교，명현감소，차차이구유통계학의의（P＜0．05）；접수방료후종류표지물강저조적110례환자근기료효현저호우승고조，차이구유통계학의의（P＜0．05）。결론혈청종류표지물CEA、CYFAR21-1、SCC、CA125적함량혹가이용래평개방료대만기NSCLC적근기효과。
Objective To investigate the relation between short-term efficacy of radiotherapy and serum levels of tumor markers in advanced non-small cell lung cancer before and after radiotherapy in patients with serum CEA , CYFAR21-1, SCC, CA125 levels change.Methods Serum levels of CEA,CYFAR21-1,SCC,CA125 in 196 cases of advanced non-small cell lung cancer patients before and after radiotherapy were retrospectively analyzed .Short-term effects were evaluated by clinical symp-toms,and the relationship between the short-term efficacy of radiotherapy and tumor markers changes was investigated .Results Among the 196 patients,109 cases of patients were effective after radiotherapy ,the total effective rate was 53.06%.The routine examination of effective cases showed that serum levels of CEA ,CYFAR21-1,SCC,CA125 significantly reduced after radiothera-py,the difference was statistically significant (P<0.05);serum levels of CEA,CYFAR21-1,SCC,CA125 significantly reduced af-ter radiotherapy in 110 patients,and their short-term efficacy was better than that those patients with increased serum tumor mark-ers,the difference was statistically significant (P<0.05).Conclusion Serum tumor markers CEA,CYFAR21-1,SCC,CA125 levels can be used to assess short-term efficacy of patients with advanced NSCLC after radiotherapy .